X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1383) 1383
Publication (152) 152
Newspaper Article (67) 67
Newsletter (37) 37
Book Review (13) 13
Transcript (12) 12
Conference Proceeding (9) 9
Book Chapter (3) 3
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bendamustine (971) 971
humans (885) 885
index medicus (753) 753
oncology (539) 539
hematology (534) 534
rituximab (485) 485
male (447) 447
bendamustine hydrochloride (446) 446
female (439) 439
aged (400) 400
middle aged (398) 398
antineoplastic combined chemotherapy protocols - therapeutic use (344) 344
chemotherapy (320) 320
lymphomas (278) 278
cancer (260) 260
treatment outcome (255) 255
adult (245) 245
care and treatment (211) 211
leukemia, lymphocytic, chronic, b-cell - drug therapy (209) 209
nitrogen mustard compounds - therapeutic use (196) 196
nitrogen mustard compounds - administration & dosage (194) 194
aged, 80 and over (187) 187
non-hodgkins-lymphoma (182) 182
therapy (173) 173
antineoplastic agents - therapeutic use (171) 171
chronic lymphocytic leukemia (164) 164
antineoplastic agents (159) 159
cyclophosphamide (158) 158
bendamustine hydrochloride - administration & dosage (156) 156
antimitotic agents (152) 152
antineoplastic combined chemotherapy protocols - adverse effects (147) 147
multicenter (143) 143
open-label (143) 143
chronic lymphocytic-leukemia (141) 141
nitrogen mustard compounds - adverse effects (136) 136
trial (135) 135
plus rituximab (132) 132
lymphoma (131) 131
fludarabine (129) 129
pharmacology & pharmacy (125) 125
bortezomib (124) 124
leukemia (122) 122
recurrence (120) 120
mantle cell lymphoma (119) 119
medicine & public health (119) 119
multiple myeloma (117) 117
disease-free survival (113) 113
phase-ii (112) 112
drug therapy (108) 108
1st-line treatment (107) 107
patients (107) 107
prognosis (107) 107
antineoplastic agents, alkylating - therapeutic use (106) 106
rituximab - administration & dosage (104) 104
survival (104) 104
transplantation (104) 104
bendamustine plus rituximab (103) 103
follicular lymphoma (102) 102
research (101) 101
bendamustine hydrochloride - therapeutic use (100) 100
phase-ii trial (97) 97
antineoplastic combined chemotherapy protocols - administration & dosage (96) 96
lymphoma, non-hodgkin - drug therapy (96) 96
analysis (95) 95
clinical trials (94) 94
antibodies, monoclonal, murine-derived - administration & dosage (92) 92
combination (92) 92
lenalidomide (91) 91
lymphoma, mantle-cell - drug therapy (91) 91
retrospective studies (89) 89
progression-free survival (88) 88
stem-cell transplantation (86) 86
animals (80) 80
non-hodgkin's lymphomas (79) 79
hematology, oncology and palliative medicine (78) 78
chlorambucil (76) 76
hemic and lymphatic diseases (76) 76
non-hodgkin lymphoma (76) 76
toxicity (76) 76
bendamustine hydrochloride - adverse effects (75) 75
efficacy (74) 74
previously untreated patients (74) 74
antineoplastic agents - administration & dosage (73) 73
antineoplastic agents - adverse effects (73) 73
drug administration schedule (73) 73
indolent (73) 73
remission induction (73) 73
multiple myeloma - drug therapy (72) 72
stem cells (72) 72
cll (71) 71
b-cell (68) 68
apoptosis (67) 67
neoplasm staging (67) 67
relapse (67) 67
salvage therapy (66) 66
ibrutinib (65) 65
internal medicine (65) 65
non-hodgkin-lymphoma (65) 65
lymphoma, follicular - drug therapy (62) 62
diagnosis (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1414) 1414
German (39) 39
Japanese (21) 21
Russian (13) 13
Polish (10) 10
French (8) 8
Spanish (5) 5
Chinese (3) 3
Czech (2) 2
Hungarian (2) 2
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5626 - 5626
Abstract Introduction Bendamustine (B) and Melflufen (Mel) are Non-Food and Drug Administration (FDA) approved novel alkylators that exert their cytotoxic... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4472 - 4472
Abstract Background: In patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), novel therapies are needed to prolong disease control.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5847 - 5847
Abstract Background and Aim: The incidence and outcomes of patients with cancer diagnoses are reported annually as SEERs in few but not all countries. Clinical... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 4781 - 4781
Abstract Background: Recent introductions of multiple myeloma (MM) chemotherapy agents have improved response and survival rates, yet substantial unmet... 
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, p. 225
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1932 - 1938
Abstract Background Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic... 
relapsed/refractory NHL | phase Ib | venetoclax | bendamustine-rituximab | Salvage Therapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Rituximab - pharmacokinetics | Bendamustine Hydrochloride - adverse effects | Chemotherapy-Induced Febrile Neutropenia - etiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Bendamustine Hydrochloride - pharmacokinetics | Lymphoma, Non-Hodgkin - pathology | Neoplasm Recurrence, Local - pathology | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Rituximab - adverse effects | Chemotherapy-Induced Febrile Neutropenia - epidemiology | Drug Administration Schedule | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Disease Progression | Sulfonamides - pharmacokinetics | Rituximab - administration & dosage | Maximum Tolerated Dose | Progression-Free Survival | Sulfonamides - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Salvage Therapy - methods | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Drug Resistance, Neoplasm - drug effects | relapsed | refractory NHL | Original | bendamustine–rituximab
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4, pp. 269 - 277
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 10/2016, Volume 146, pp. 852 - 860
Journal Article
Apoptosis, ISSN 1360-8185, 06/2017, Volume 22, Issue 6, pp. 827 - 840
Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biological process including cell cycle and apoptosis.... 
Bendamustine | Synergistic effect | Lymphoma | Ricolinostat | Apoptosis | MULTIPLE-MYELOMA | MULTICENTER | AGGRESOME FORMATION | ACY-1215 | ACETYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MECHANISMS | CELL BIOLOGY | THIOREDOXIN | IN-VIVO | LENALIDOMIDE | HISTONE DEACETYLASE INHIBITORS | Bendamustine Hydrochloride - therapeutic use | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Histone Deacetylase 6 - metabolism | Lymphoma - drug therapy | Mesenchymal Stromal Cells - cytology | Microtubules - metabolism | Tubulin - metabolism | Caspases - metabolism | Microtubules - drug effects | Interleukin-10 - metabolism | Lymphoma - pathology | Clone Cells | Proto-Oncogene Proteins c-akt - metabolism | Hydroxamic Acids - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Mesenchymal Stromal Cells - drug effects | Endoplasmic Reticulum Stress - drug effects | Histone Deacetylase 6 - antagonists & inhibitors | Cell Cycle Proteins - metabolism | Pyrimidines - pharmacology | Enzyme Activation - drug effects | Drug Synergism | Acetylation - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Bendamustine Hydrochloride - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Proto-Oncogene Proteins c-bcl-2 | Cell Cycle - drug effects
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, p. 86
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 27, pp. 3293 - 3299
Journal Article